Tvardi Therapeutics, Inc. (NASDAQ:TVRD – Get Free Report) shares rose 2.4% during trading on Thursday . The company traded as high as $22.85 and last traded at $22.67. Approximately 19,929 shares were traded during trading, a decline of 77% from the average daily volume of 87,609 shares. The stock had previously closed at $22.13.
Analysts Set New Price Targets
TVRD has been the subject of a number of analyst reports. Wall Street Zen raised shares of Tvardi Therapeutics to a “hold” rating in a report on Saturday, May 24th. Piper Sandler initiated coverage on shares of Tvardi Therapeutics in a report on Thursday, June 12th. They set an “overweight” rating and a $78.00 target price for the company. Finally, Oppenheimer initiated coverage on shares of Tvardi Therapeutics in a report on Wednesday, May 21st. They set an “outperform” rating and a $65.00 target price for the company.
Check Out Our Latest Research Report on TVRD
Tvardi Therapeutics Trading Up 2.4%
About Tvardi Therapeutics
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.
Read More
- Five stocks we like better than Tvardi Therapeutics
- How to Read Stock Charts for Beginners
- BigBear.ai: Why a 90% Rally Could Be Just the Start
- How to Buy Gold Stock and Invest in Gold
- 5 Hot Stocks With Summer Buybacks You Can Cash In On
- ESG Stocks, What Investors Should Know
- Why Now Could Be the Smartest Time to Buy Crypto Stocks
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
